基因组编辑
嵌合抗原受体
生物
细胞毒性T细胞
病毒载体
计算生物学
TRAC公司
内生
转导(生物物理学)
细胞生物学
清脆的
细胞培养
基因
基因座(遗传学)
细胞
电池类型
诱导多能干细胞
遗传增强
体外
基因靶向
功能(生物学)
癌症研究
插入(复合材料)
HEK 293细胞
基因传递
转录激活物样效应核酸酶
抗原
T细胞
表型
遗传学
转染
Jurkat细胞
锌指核酸酶
作者
Oliver Gough,Christos Georgiadis,Roland Preece,Renuka Kadirkamanathan,Waseem Qasim
标识
DOI:10.1016/j.ymthe.2026.10.038
摘要
Chimeric Antigen Receptor (CAR) T cells are commonly generated using gamma-retroviral or lentiviral vectors given their efficiency and stable integration, but vector supply constraints have created bottlenecks to wider access. Using a combination of lentiviral transduction and genome editing, ‘universal' donor CAR-T cells devoid of endogenous TCRαβ and suitable for multiple recipients are also under investigation as ‘off-the-shelf' therapies. In addition, nuclease mediated insertion by homology-directed repair (HDR) of CAR genes delivered by Adeno Associated Virus into the TRAC locus has been reported to mediate superior tumour clearance. We investigated alternative entirely virus-free procedures to insert synthetic DNA encoding CAR genes at either TRAC or CD3ζ loci in direct comparison to lentiviral generated universal 41BB-CD3ζ-CAR T cells. While non-viral manufacture was successful and in vitro cytotoxic function was comparable, in vivo inhibition of human leukemia in xenograft murine models was not superior to lentiviral products. Non-viral approaches offer attractive prospects for sophisticated editing and precise CAR insertion and may offer valuable therapeutic options, but careful preclinical evaluation and well-designed clinical trials benchmarked against existing lentiviral approaches are recommended.
科研通智能强力驱动
Strongly Powered by AbleSci AI